The importance of timely and appropriately-sized pharmacovigilance studies in the detection of safety signals: Lessons learned from the erythropoiesis stimulating agents (ESAs) controversy

6532 Background: In 1989 and 1993, epoetin was approved to treat patients with anemia associated with chronic kidney disease (CKD) and with chemotherapy for cancer. Since 2006, risks of ESA-associa...